文献速递神经肿瘤

脑肿瘤临床试验入组障碍与对策

Barriers to accrual and enrollment in brain tumor trials.
PubMed 文献 · Neuro Oncol · 2019-01-01

该文指出脑肿瘤患者生存改善有限的部分可修正因素是临床试验入组不佳。患者与神经肿瘤医生的调查提示,临床医生在讨论试验和转介方面做得不够,但美国癌症协会癌症行动网络数据显示多数被邀请入组的合格肿瘤患者愿意参加。SNO与RANO工作组、患者倡导组织及ABTC等合作,目标在未来5年将临床试验入组翻倍。

要点

  • 脑肿瘤临床试验入组不佳是可干预的进步障碍。
  • 医生与患者讨论试验及转介方面存在不足。
  • 多数被邀请入组的合格肿瘤患者愿意参加试验。

核心结论

  • 脑肿瘤临床试验入组不佳是神经肿瘤学进展的可修正障碍,需多方合作改善。

研究设计与样本

  • 本文为神经肿瘤学临床试验入组障碍的综述,基于患者与医生调查及美国癌症协会癌症行动网络数据。

主要发现

  • 脑肿瘤患者与神经肿瘤医生的调查提示,临床医生在讨论临床试验和转介患者方面做得不够。
  • 美国癌症协会癌症行动网络数据显示,多数被邀请入组的合格肿瘤患者愿意参加临床试验。

临床怎么用

  • 神经外科及神经肿瘤医生应主动与患者讨论临床试验并适时转介。
  • 可参考SNO与RANO等合作框架推动入组改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Many factors contribute to the poor survival of malignant brain tumor patients, some of which are not easily remedied. However, one contributor to the lack of progress that may be modifiable is poor clinical trial accrual. Surveys of brain tumor patients and neuro-oncology providers suggest that clinicians do a poor job of discussing clinical trials with patients and referring patients for clinical trials. Yet, data from the Cancer Action Network of the American Cancer Society suggest that most eligible oncology patients asked to enroll on a clinical trial will agree to do so. To this end, the Society for Neuro-Oncology (SNO) in collaboration with the Response Assessment in Neuro-Oncology (RANO) Working Group, patient advocacy groups, clinical trial cooperative groups, including the Adult Brain Tumor Consortium (ABTC), and other partners are working together with the intent to double clinical trial accrual over the next 5 years. Here we describe the factors contributing to poor clinical trial accrual in neuro-oncology and offer possible solutions.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Lee EQ, Chukwueke UN, Hervey-Jumper SL, et al. Barriers to accrual and enrollment in brain tumor trials. Neuro Oncol. 2019. PMID: 31175826. doi:10.1093/neuonc/noz104

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。